Regulus Therapeutics (RGLS) Stock Price, Quote & News

Company Profile

Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was formerly known as Regulus Therapeut...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 202 6300

Website: www.regulusrx.com

Address:

4224 Campus Point Court, Suite 210, San Diego, United States

BioRich Mar. 6 at 2:32 PM

$SLS Get a kick out of the childish bro basher trying to say I missed out on $RGLS. I bought at $0.93 and made a massive profit when it got bought out. Oh, and how cute, I have $SLS on my post as well. Stop blind hating $SLS board. If you believe in the product, believe in the product. If you attack Bulls that have simple questions, you put off scammish vibes and raise more questions. $SLS doesn't need that right now. Do better.

3 · Reply

TheRealShortSqueezy Mar. 3 at 2:57 PM

TheRealShortSqueezy @TheShortSqueezy · 6s $ATAI: Recent News Strengthens Analyst Conviction ATAIBeckley is seeing increasing analyst conviction following the release of key clinical milestones and recent business developments. Latest Analyst Update: HC Wainwright & Co. has maintained its Buy rating on ATAI while raising its price target to $25.00 from $15.00, a 66.67% increase. Recent Analyst Coverage: Guggenheim – $11 price target (Jan 20, 2026) JonesTrading – $16 price target Canaccord Genuity – PT raised to $14 from $11 (+27%) Needham – $12 price target Institutional Activity: ARK Invest increased its position in Q4 2025 by 1,286,446 shares (+63.7%) ARK now holds 3,305,997 shares. Rising price targets, institutional buying, and continued execution reflect growing confidence in ATAIBeckley’s strategy and long-term potential. 📊 Communicated disclaimer: https://bit.ly/4ci8Ftu Sector Peers: $RLMD $SLS $ANIX $RGLS

0 · Reply

skyrockets_Inc Feb. 27 at 3:59 PM

$RLYB it's still tracking the $RGLS example (which got bought out a month after their data) within a few percentage points. RGLS was 1.40 pre-data....5 days after $2, two weeks later $4, and then a week later $8 buyout for a total of 4 weeks post-data. Next stops for us IMO, I assume news within Q1 (by March 31): $7 --> $10 --> $15 and then announcement (buyout / PIPE / partnership) --> $30+

0 · Reply

TheRealShortSqueezy Feb. 26 at 2:01 PM

$ATAI Delivers Major Development News🔬🧬 ATAI Life Sciences continues advancing its clinical pipeline following multiple recent milestones. Recent Key Milestones 🎯 The company has reported several important advancements across its pipeline and leadership: ➡️Positive Phase 2a topline results for EMP-01 in social anxiety disorder, providing early clinical proof-of-concept ➡️Continued development of core pipeline assets, including: 🥇BPL-003: progressing toward late-stage development 🥈VLS-01: currently in Phase 2 clinical trials ➡️Strengthened executive leadership with the appointment of a new Chief Financial Officer These developments highlight accelerating pipeline momentum heading into 2026 Investor Conferences 👇 🗓️March 4th: TD Cowen 46th Annual Health Care Conference 🗓️March 10th: Jefferies 2026 Biotech on the Beach 🗓️March 11th: Leerink Global Healthcare Conference Communicated Disclaimer : https://bit.ly/3OCJhol Sector Peers: $SLS $ANIX $RGLS $VNDA

1 · Reply

skyrockets_Inc Feb. 25 at 7:02 PM

$RLYB cont. from post below. 4). Data released Feb 14. Good efficacy and safety. Now company can talk again and is out of 'black period' . Now that they know plan going forward they can now share data with potential investors (PIPE theory) and/or suitors (parnter/buyout theory). Hence the 'clock' started on Feb 17. From Jan to Feb 17 they did not even know the future of their own company. Makes no sense that they would be sharing data w/ investors at this point. 5). Since data: Stock has rallied almost 50% . Constant buying pressure and volume pushing stock up to closer and closer to intrinsic value. Following the $RGLS example. Data , no reaction, then price adjustment. Then the buyout came for $RGLS a month later. Investors are just now seeing the data for the first time and a deal should take 30-60 days to complete. Expecting something soon . Price action seems to corroberate my theory as well. GLTA !

0 · Reply

IIStock_LesnarII Jan. 29 at 9:05 PM

$CATX $FEED $RGLS $RPGL $AIB SGN NEEDS SLAPS

0 · Reply

IIStock_LesnarII Jan. 29 at 9:05 PM

$AIB $FEED $RGLS $CATX $RPGL Slap that Ask! Basically no walls here on the way up

0 · Reply

IIStock_LesnarII Jan. 29 at 8:42 PM

$AIB $FEED $RGLS $SER $SGMO SGN— After hours party? LFG

0 · Reply

IIStock_LesnarII Jan. 29 at 8:14 PM

$AIB $TCGL $RGLS $CATX $RPGL SGN —Cheapies here

0 · Reply

IIStock_LesnarII Jan. 29 at 7:48 PM

$AIB $RGLS $CATX $FEED $RPGL

0 · Reply

Novartis completes acquisition of Regulus Therapeutics

NVS

Jun 25, 2025, 1:00 AM EDT - 9 months ago

Novartis announces expiration of Regulus Therapeutics tender offer

NVS

May 27, 2025, 7:56 AM EDT - 10 months ago

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

NVS

May 8, 2025, 4:05 PM EDT - 11 months ago

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

May 4, 2025, 12:25 PM EDT - 11 months ago

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

Apr 30, 2025, 12:24 PM EDT - 11 months ago

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher

NVS

Apr 30, 2025, 11:22 AM EDT - 11 months ago

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

NVS

Apr 30, 2025, 7:50 AM EDT - 11 months ago

Novartis to Acquire Regulus in $1.7 Billion Deal

NVS

Apr 30, 2025, 7:25 AM EDT - 11 months ago

Novartis to buy Regulus Therapeutics for up to $1.7 billion

NVS

Apr 30, 2025, 7:10 AM EDT - 11 months ago

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

NVS

Apr 30, 2025, 7:00 AM EDT - 11 months ago

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

NVS

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

Mar 27, 2025, 12:59 PM EDT - 1 year ago

Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

Mar 4, 2025, 8:00 AM EST - 1 year ago

Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 1 year ago

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

Nov 26, 2024, 8:00 AM EST - 1 year ago

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Nov 7, 2024, 4:05 PM EST - 1 year ago

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes

May 16, 2024, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer

May 9, 2024, 4:05 PM EDT - 2 years ago

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

May 6, 2024, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series

Apr 10, 2024, 12:51 PM EDT - 2 years ago

Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD

Mar 21, 2024, 4:05 PM EDT - 2 years ago

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

Mar 12, 2024, 6:32 AM EDT - 2 years ago

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

Mar 12, 2024, 6:30 AM EDT - 2 years ago

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jan 2, 2024, 4:05 PM EST - 2 years ago

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Nov 22, 2023, 8:00 AM EST - 2 years ago

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 9, 2023, 4:05 PM EST - 2 years ago

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sep 20, 2023, 7:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sep 13, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Aug 23, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

Aug 2, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jul 18, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference

Jun 27, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jun 23, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D.

Jun 20, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital

BioRich Mar. 6 at 2:32 PM

3 · Reply

TheRealShortSqueezy Mar. 3 at 2:57 PM

0 · Reply

skyrockets_Inc Feb. 27 at 3:59 PM

0 · Reply

TheRealShortSqueezy Feb. 26 at 2:01 PM

1 · Reply

skyrockets_Inc Feb. 25 at 7:02 PM

0 · Reply

IIStock_LesnarII Jan. 29 at 9:05 PM

$CATX $FEED $RGLS $RPGL $AIB SGN NEEDS SLAPS

0 · Reply

IIStock_LesnarII Jan. 29 at 9:05 PM

$AIB $FEED $RGLS $CATX $RPGL Slap that Ask! Basically no walls here on the way up

0 · Reply

IIStock_LesnarII Jan. 29 at 8:42 PM

$AIB $FEED $RGLS $SER $SGMO SGN— After hours party? LFG

0 · Reply

IIStock_LesnarII Jan. 29 at 8:14 PM

$AIB $TCGL $RGLS $CATX $RPGL SGN —Cheapies here

0 · Reply

IIStock_LesnarII Jan. 29 at 7:48 PM

$AIB $RGLS $CATX $FEED $RPGL

0 · Reply

IIStock_LesnarII Jan. 29 at 7:45 PM

$AIB $FEED $RGLS $TGHL $RPGL SGN — After the break of .235— this can get back into the .27 cent range and re-test that support

0 · Reply

IIStock_LesnarII Jan. 29 at 7:44 PM

$AIB $RGLS $CATX $RPGL $SGMO SGN — Reversal inbound LFG! BULLS Let’s go! Let’s get this above .23-.24 for after hour moves

0 · Reply

IIStock_LesnarII Jan. 29 at 7:37 PM

$AIB $FEED $CATX $RGLS $RPGL SGN Looking for Group Let’s push this up a bit from here

0 · Reply

IIStock_LesnarII Jan. 29 at 7:27 PM

$AIB $FEED $TIRX $RGLS $CATX SGN - Let’s push this into .23 and then go from there Buying some more here

1 · Reply

IIStock_LesnarII Jan. 29 at 7:13 PM

$AIB $FEED $RGLS $CATX Buying more SGN here Might as well average down more at the very least Let’s see how it goes by 4pm

0 · Reply

IIStock_LesnarII Jan. 29 at 7:06 PM

$AIB $FEED $RGLS $CATX $RPGL SGN can still go from here, keep pressure here LFG BULLS

0 · Reply

IIStock_LesnarII Jan. 29 at 6:56 PM

$AIB $RGLS $CATX

0 · Reply

IIStock_LesnarII Jan. 29 at 6:42 PM

$AIB $RGLS $FEED $CATX SGX — cheapie buys here This company has great news Volume is high Shorts are struggling

1 · Reply

Gemini367 Jan. 7 at 11:20 AM

$VTYX $RGLS $AKRO $VKTX . Congrats to all, who are still holding VTYX. Potential bidding war can can send it much higher. Good luck.

0 · Reply

BinaryLogic Jan. 7 at 2:25 AM

$VTYX [Correct] Congratulations to those who listened from $1.0-1.7. You only had to wait 6-12mos. Concurrently-you could have done well from my analyses on $RANI from $0.4, $IMRX from $1.0, SCNX from $0.5->3.0, $RGLS from $0.8, $VKTX from $17. Again-invest to your own risk tolerance and time horizon, diversify your positions and do your own analysis to build your conviction. https://www.investing.com/news/stock-market-news/ventyx-biosciences-stock-surges-after-eli-lilly-acquisition-talks-93CH-4433423

0 · Reply

Shroomm Dec. 17 at 10:22 AM

$RGLS

0 · Reply

Runescapeftw1337 Dec. 10 at 3:33 PM

$RGLS

0 · Reply

Market Cap	564.95M
Revenue (ttm)	0.00
Net Income (ttm)	-46.36M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	9,342,400
Avg Vol	2,425,440
Day's Range	N/A - N/A
Shares Out	69.23M
Stochastic %K	72%
Beta	0.35
Analysts	Sell
Price Target	$8.80